# Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

> **NCT07116928** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 1244 (estimated)

## Conditions studied

- T2DM (Type 2 Diabetes Mellitus)
- CKD - Chronic Kidney Disease

## Interventions

- **DRUG:** ganagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07116928
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-30
- **Primary completion:** 2031-10-30
- **Final completion:** 2031-12-30
- **Target enrollment:** 1244 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07116928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07116928, "Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07116928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*